Navigation Links
Vasogen Provides Corporate Update
Date:1/6/2009

t constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to complete a sale, merger, acquisition, or other strategic alternative, statements regarding the status of development, or expenditures relating to the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-
'/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... Ill. , July 18, 2014 /PRNewswire/ ... infographic highlighting AbbVie and Shire,s complementary fit ... A copy of the infographic ... at:  http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents In ... Code, a copy of this announcement will ...
(Date:7/18/2014)... Switzerland , July 18, 2014 ... Education in Animal Research for the third consecutive year. ... State University, will attend a 1-week course at Zürich ... of the 3Rs (Replace, Reduce, Refine). As head of ... Popov has been given the task of adapting experimental ...
(Date:7/17/2014)... July 17, 2014  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the development and commercialization of products for the treatment ... release results for the second quarter of 2014 on ... The Company will host a conference call ... during which Vanda management will discuss the second quarter ...
(Date:7/17/2014)... Australia , July 17, 2014  Prana Biotechnology ... provided an update on its clinical development program for ... the Florey Institute of Neuroscience and Mental Health, The ... Phase 2 IMAGINE and EURO trials in his presentation ... Copenhagen, Denmark . The presentation is ...
Breaking Biology Technology:NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 2NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 3NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 4NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 5NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 6NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 7Young Moscovite Researcher Receives this Year's "Basel Declaration Award for Education in Animal Research" 2Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014 2Prana Alzheimer's disease Development Program update 2Prana Alzheimer's disease Development Program update 3Prana Alzheimer's disease Development Program update 4Prana Alzheimer's disease Development Program update 5
... 17 Repligen Corporation,(Nasdaq: RGEN ) announced today ... Herlihy, Ph.D., will present at the 2008 UBS,Global Life ... EDT at the Grand Hyatt Hotel, 455 Madison Avenue, ... presentation will be available via,Repligen,s website at http://www.repligen.com ...
... 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... on,endocrine therapy and oncology, today announced that its ... CA, will present a,company overview at the upcoming ... Tuesday, September 23, 2008 at 3:25 pm (eastern,time), ...
... Coast Oncology to be the first private practice in ... offer state-of-the-art proton radiation ... M.D.,Medical Director, First Coast Oncology, Jacksonville, FL is pleased ... Monarch250(TM),Proton Therapy System from Still River Systems, Inc, in ...
Cached Biology Technology:Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT 2Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT 3First Coast Oncology to Offer Next Generation Proton Therapy 2First Coast Oncology to Offer Next Generation Proton Therapy 3
(Date:7/21/2014)... hotspots in areas across Riau province on Sunday, July ... following a decline in rainfall. The number of ... what had been reported one day prior, which had ... in six regencies and municipalities, most of which were ... haze it creates could potentially spread via winds to ...
(Date:7/21/2014)... to climate change, due to greenhouse gasses emitted by ... the rise and that beef cattle are responsible for ... animals. It is published by Climactic Change . ... it comes to climate change. It is released by ... portion of greenhouse gas totals. But methane and nitrous ...
(Date:7/21/2014)... causing problems for the world,s water sources. In ... stormwater runoff to be one of the top ... lakes, ponds, reservoirs, bays, and estuaries. The pollutants ... wildlife populations, foul drinking water, and make recreational ... University are looking to rain gardens as one ...
Breaking Biology News(10 mins):Climate: Meat turns up the heat 2Filter bed substrates, plant types recommended for rain gardens 2
... plants ship sugars from their leaves to flowers, roots, ... engineering techniques, Cornell researchers have finally proven a long-standing ... deepen understanding of basic plant biology but could one ... photosynthetic rates, yields and carbon dioxide intake. This might ...
... to better understand the relationship between the bacteria ... defense cells that engulf them., The researchers have ... tuberculosis does not react when immune system ... bacterium,s genes become activated minutes after the pathogen ...
... winners of its student travel award to attend the ... Biophysics Congress in Long Beach, California, February 2-6, 2008. ... on scientific merit, with priority given to those who ... awardee receives a travel grant and will be recognized ...
Cached Biology News:Cornell researchers prove how plants transport sugars 2Cornell researcher seeks clues to how tuberculosis infects cells 2Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5
... The thermostable dUTPase(pyrococcus fruriosus) maximizes the ... DNA polymerases). It removes contaminating ... dNTP solutions. The presence of ... reaction can prevent dUTP misincorporation by ...
... comes with a shutter (controlled via a TTL ... Deuterium Light Source produces a powerful, stable output ... the light source are available, providing a wavelength ... lamp provides peak-to-peak stability of less than 0.005% ...
... The NOVOstar is an exciting product for ... cell-based assays required the use of expensive ... for scientists in the assay development stage. ... for cell-based assays as well as any ...
... intactness and detects events that dissipate ... Benefits: Fast, simple, and ... and for assaying mitochondria intactness ... for the detection of changes in ...
Biology Products: